D Enache1,2, S-M Fereshtehnejad3, I Kåreholt4,5, P Cermakova6,7, S Garcia-Ptacek3,8, K Johnell4, D Religa6,8, V Jelic3,8, B Winblad6,8, C Ballard9, D Aarsland6,8,10, J Fastbom4, M Eriksdotter3,8. 1. Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. daniela.enache@ki.se. 2. Southwest Psychiatry, Karolinska University Hospital, Huddinge, Sweden. daniela.enache@ki.se. 3. Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. 4. Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. 5. Institute of Gerontology, School of Health Sciences, Jönköping University, Jönköping, Sweden. 6. Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. 7. International Clinical Research Center and St. Anne's University Hospital, Brno, Czech Republic. 8. Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden. 9. Wolfson Centre for Age-Related Diseases, King's College London, London, UK. 10. Center for Age-Related Diseases, Psychiatric Clinic, Stavanger University Hospital, Stavanger, Norway.
Abstract
BACKGROUND: The association between mortality risk and use of antidepressants in people with dementia is unknown. OBJECTIVE: To describe the use of antidepressants in people with different dementia diagnoses and to explore mortality risk associated with use of antidepressants 3 years before a dementia diagnosis. METHODS: Study population included 20 050 memory clinic patients from the Swedish Dementia Registry (SveDem) diagnosed with incident dementia. Data on antidepressants dispensed at the time of dementia diagnosis and during 3-year period before dementia diagnosis were obtained from the Swedish Prescribed Drug Register. Cox regression models were used. RESULTS: During a median follow-up of 2 years from dementia diagnosis, 25.8% of dementia patients died. A quarter (25.0%) of patients were on antidepressants at the time of dementia diagnosis, while 21.6% used antidepressants at some point during a 3-year period before a dementia diagnosis. Use of antidepressant treatment for 3 consecutive years before a dementia diagnosis was associated with a lower mortality risk for all dementia disorders and in Alzheimer's disease. CONCLUSION: Antidepressant treatment is common among patients with dementia. Use of antidepressants during prodromal stages may reduce mortality in dementia and specifically in Alzheimer's disease.
BACKGROUND: The association between mortality risk and use of antidepressants in people with dementia is unknown. OBJECTIVE: To describe the use of antidepressants in people with different dementia diagnoses and to explore mortality risk associated with use of antidepressants 3 years before a dementia diagnosis. METHODS: Study population included 20 050 memory clinic patients from the Swedish Dementia Registry (SveDem) diagnosed with incident dementia. Data on antidepressants dispensed at the time of dementia diagnosis and during 3-year period before dementia diagnosis were obtained from the Swedish Prescribed Drug Register. Cox regression models were used. RESULTS: During a median follow-up of 2 years from dementia diagnosis, 25.8% of dementiapatients died. A quarter (25.0%) of patients were on antidepressants at the time of dementia diagnosis, while 21.6% used antidepressants at some point during a 3-year period before a dementia diagnosis. Use of antidepressant treatment for 3 consecutive years before a dementia diagnosis was associated with a lower mortality risk for all dementia disorders and in Alzheimer's disease. CONCLUSION: Antidepressant treatment is common among patients with dementia. Use of antidepressants during prodromal stages may reduce mortality in dementia and specifically in Alzheimer's disease.
Authors: A Calderón-Larrañaga; D L Vetrano; L Ferrucci; S W Mercer; A Marengoni; G Onder; M Eriksdotter; L Fratiglioni Journal: J Intern Med Date: 2018-11-22 Impact factor: 8.989
Authors: Hana Marie Broulikova; Marketa Arltova; Marie Kuklova; Tomas Formanek; Pavla Cermakova Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Alan J McMichael; Evi Zafeiridi; Peter Passmore; Emma L Cunningham; Bernadette McGuinness Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472